EF Hutton Maintains Buy on Marinus Pharma, Maintains $23 Price Target

Benzinga · 10/17 12:54
EF Hutton analyst Jason Kolbert maintains Marinus Pharma (NASDAQ:MRNS) with a Buy and maintains $23 price target.